+44 (0)20 3910 4640 hello@symmetron.net

Idiopathic Pulmonary Fibrosis

 

A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK

PharmacoEconomics. 2017 Apr;35(4):479-491

Authors

Rinciog C, Watkins M, Chang S, Maher TM, LeReun C, Esser D, Diamantopoulos A 

Process

\

An original Markov model was designed to capture the changes in the condition of adults with IPF

\

Systematic and targeted literature reviews

\

Regression analyses of phase II clinical data

\

Advisory panel

Publications in other disease areas

Atrial fibrillation

Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke

Cancer

Societal costs of Er+/Her2- advanced or metastatic breast cancer in post-menopausal women in the United Kingdom

Idiopathic pulmonary fibrosis

The burden of illness of idiopathic pulmonary fibrosis: a comprehensive evidence review

Psoriasis

The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis

Rheumatoid arthritis

Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK

 

Venous thromboembolism

Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective